drugset / Trial / NCT06596876

A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuations

NCT06596876

Phase 3 Completed 165 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is a multicenter, randomized, double-blind, double-dummy, active-controlled, Phase III clinical study. The aim of this trial is to evaluated the efficacy and assessed the safety of HRG2010 compared with a sustained-release cabridopa-levodopa formulation in Parkinson's Disease With Motor Fluctuations.

Timeline

Start
2024-11-06
Primary completion
2025-10-09
Completion
2026-01-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbidopa/Levodopa Unknown Oral
Subject HRG2010 Unknown Oral

Indications